- Home
- LIEN vs RCEL Comparison
LIEN vs RCEL Comparison
Compare LIEN & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIEN
- RCEL
- Stock Information
- Founded
- LIEN 2021
- RCEL N/A
- Country
- LIEN United States
- RCEL United States
- Employees
- LIEN N/A
- RCEL N/A
- Industry
- LIEN
- RCEL Medical/Dental Instruments
- Sector
- LIEN
- RCEL Health Care
- Exchange
- LIEN NYSE
- RCEL Nasdaq
- Market Cap
- LIEN 278.9M
- RCEL 308.6M
- IPO Year
- LIEN 2022
- RCEL N/A
- Fundamental
- Price
- LIEN $12.43
- RCEL $9.75
- Analyst Decision
- LIEN
- RCEL Buy
- Analyst Count
- LIEN 0
- RCEL 5
- Target Price
- LIEN N/A
- RCEL $17.25
- AVG Volume (30 Days)
- LIEN 5.0K
- RCEL 191.4K
- Earning Date
- LIEN 03-26-2025
- RCEL 02-13-2025
- Dividend Yield
- LIEN 11.13%
- RCEL N/A
- EPS Growth
- LIEN N/A
- RCEL N/A
- EPS
- LIEN 0.67
- RCEL N/A
- Revenue
- LIEN $12,681,914.00
- RCEL $64,251,000.00
- Revenue This Year
- LIEN $71.81
- RCEL $62.11
- Revenue Next Year
- LIEN $113.93
- RCEL $31.19
- P/E Ratio
- LIEN $18.32
- RCEL N/A
- Revenue Growth
- LIEN 22.94
- RCEL 28.14
- 52 Week Low
- LIEN $8.38
- RCEL $7.51
- 52 Week High
- LIEN $13.38
- RCEL $18.93
- Technical
- Relative Strength Index (RSI)
- LIEN N/A
- RCEL 50.10
- Support Level
- LIEN N/A
- RCEL $8.37
- Resistance Level
- LIEN N/A
- RCEL $11.25
- Average True Range (ATR)
- LIEN 0.00
- RCEL 0.55
- MACD
- LIEN 0.00
- RCEL 0.22
- Stochastic Oscillator
- LIEN 0.00
- RCEL 47.92
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company's investment objective is to maximize risk-adjusted returns on equity for its stockholders by investing primarily in direct loans to privately held middle-market companies, with a focus on cannabis companies.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.